Liquidia Corporation (LQDA) Stock Analysis & Investment Frameworks
Liquidia Corporation (LQDA) stock analysis on Invetso. Review Liquidia Corporation’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Liquidia Corporation Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Medical - Pharmaceuticals
- Country: US
Liquidia Corporation Key Financial Metrics
- Market Cap: $4.00B
- Revenue: $158.32M
- ROE: 149.64%
- ROIC: 46.86%
- Dividend Yield: N/A
About Liquidia Corporation
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.